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Tissue-Type Plasminogen Activator
Is a Multiligand Cross- Structure Receptor
passes the 13 residues 148–160 [1]. Based on the amino-
acid sequence of this region, we made two peptides:
fibrin-derived peptide 13 (FP13) (148–160: KRLEVDIDI
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Summary
Fibrin-Derived Peptides Form Cross- Sheets
Tissue-type plasminogen activator (tPA) regulates fi- The above experiments show that the binding of tPA
brin clot lysis by stimulating the conversion of plasmin- to the two peptides occurs through distinct types of
ogen into the active protease plasmin [1]. Fibrin is interaction, one supporting tPA-mediated plasminogen
required for efficient tPA-mediated plasmin genera- activation, the other not. We considered the possibility
tion and thereby stimulates its own proteolysis. Sev- that differences in the peptide structure could underlie
eral fibrin regions can bind to tPA [1], but the structural the difference in cofactor activity. The relative contribu-
basis for this interaction is unknown. Amyloid  (A) tion of random coils,  sheets, and  helices to the
is a peptide aggregate that is associated with neuro- structure of the peptides in solution was studied via
toxicity in brains afflicted with Alzheimer’s disease [2]. circular-dichroism measurements. Strikingly, we found
Like fibrin, it stimulates tPA-mediated plasmin forma- that FP13 was in a 100%  sheet conformation with a
tion [3–5]. Intermolecular stacking of peptide back- characteristic minimum at 215 nm and a maximum at
bones in  sheet conformation underlies cross-
190 nm (Figure 2A). In contrast, FP10 was completely
structure in amyloid peptides [6]. We show here that
randomly coiled, with a minimum observed at 198 nmfibrin-derived peptides adopt cross- structure and
(Figure 2A). Therefore, it seems likely that structural dif-form amyloid fibers. This correlates with tPA binding
ferences underlie the differences in the ability of theseand stimulation of tPA-mediated plasminogen activa-
peptides to activate tPA.tion. Prototype amyloid peptides, including A and
Given the high  sheet content in FP13 and givenislet amyloid polypeptide (IAPP) (associated with pan-
the finding that amyloid  (A) supports plasminogencreatic  cell toxicity in type II diabetes [7]), have no
activation by tPA [3–5], we tested whether FP13 is ansequence similarity to the fibrin peptides but also bind
amyloid peptide with cross- sheet conformation.to tPA and can substitute for fibrin in plasminogen
Congo Red binds to amyloid peptide aggregates, irre-activation by tPA. Moreover, the induction of cross-
spective of the amino acid sequence [8]. Dried samplesstructure in an otherwise globular protein (endostatin)
of FP10 and FP13 were stained with Congo Red andendows it with tPA-activating potential. Our results
examined by light microscopy. Figure 2B shows thatclassify tPA as a multiligand receptor and show that
FP13 dried as aggregates that readily bound Congocross- structure is the common denominator in tPA
Red; it displays the characteristic green birefringencebinding ligands.
when examined under polarized light. In contrast, FP10
dried as a uniform film that did not bind Congo Red (ourResults
unpublished data).
Thioflavin T (ThT) is a fluorescent indicator of cross-tPA-Mediated Plasminogen Activation
sheets in solution [8]. By incubating the peptide solu-by Fibrin-Derived Peptides
tions with increasing concentrations of ThT and subse-One of the amino-acid sequences within the fibrin 
chain that supports tPA binding and activation encom- quently measuring fluorescence emission, we found that
FP13, but not FP10, enhanced ThT fluorescence (Figure
2C). Thus, the high content of  sheets in FP13 presum-4 Correspondence: m.gebbink@azu.nl
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maxima at 4.7, 11.7, and 23.4 A˚. The fiber axis with its
4.7 A˚ hydrogen bond repeat distance is oriented along
the vertical capillary axis. The 11.7 A˚ repeat is perpendic-
ular to that. The perpendicular orientation of the 4.7 A˚
and 11.7 A˚ distances is typical for cross- sheets. The
23.4 A˚ reflection that, like the 11.7 A˚ reflection, is ori-
ented horizontally, signals higher ordering in the in-
tersheet direction. Rough estimation of the crystallite
sizes from the width of the reflections gives 120 A˚ for
the fiber direction and 40–50 A˚ for the intersheet direc-
tion. This amounts to approximately 25  strands being
hydrogen-bonded into an array of about 4 cross-
sheets.
As a result of cross- sheet formation, peptides may
undergo fibrillogenesis [6], and such fibers can be visu-
alized with transmission electron microscopy (TEM). We
therefore examined single drops of peptide solutions by
TEM. We found that FP13, but not FP10 (our unpublished
data), formed unbranched fibrils that were about 5 nm
thick, with lengths ranging from 250 to 1000 nm (Figure
2E). These dimensions are within the range of dimen-
sions found for other amyloid peptides [10].
Thus, FP13 is an amyloid peptide with cross- sheet
conformation, it binds to tPA, and it stimulates tPA-
mediated plasminogen activation. In contrast, FP10 is
in a random-coil conformation and binds to tPA through
its C-terminal lysine residue without stimulating tPA-
mediated plasmin formation.
tPA Binding and Plasminogen Activation
by Cross- Sheet Peptides Irrespective
of Their Amino Acid Sequences
The above results prompted us to investigate the bind-
ing characteristics of several amyloid peptides to tPA.
A stimulates tPA-mediated plasmin formation [3–5]
but, to our knowledge, no binding data have been pub-
lished. To test tPA binding to A and to other amyloid
peptides, we performed solid-phase binding assays and
detected bound tPA by ELISA. Figure 3A shows that
tPA binds to A with high affinity (6.7 nM), as it does to
the fibrin peptides. Human islet amyloid polypeptide
(hIAPP) is a 37 amino acid peptide that has amyloido-
genic properties and is found deposited in the islets of
Langerhans in the pancreas of type II diabetic patients.
It acts as a diabetogenic factor, presumably by beingFigure 1. tPA Binding and Plasminogen Activation by Fibrin-Derived
toxic to the insulin-producing  cells [7]. The hIAPPPeptides
amino acid sequence is unrelated to that of A or the(A) Plasminogen (0.1 mg/ml) and tPA (200 pM) were incubated with
fibrin peptides. We found that, like A and the fibrinthe fibrin-derived peptides (5 M) or with control buffer. The conver-
sion of plasminogen to plasmin was followed over a period of time peptides, hIAPP binds to tPA with high affinity (Kd  1.8
by measurement of plasmin activity with a chromogenic substrate nM; Figure 3B).
(S-2251). Next, we tested the capacity of these two distinct
(B) Binding of FP13 to tPA. FP13 was coated onto plastic and was preaggregated amyloid peptides (A and hIAPP) to sub-
overlayed with the indicated concentrations of tPA. tPA binding was
stitute for fibrin in stimulating tPA-mediated plasmino-then assessed with the polyclonal anti-tPA antibody 385R in an
gen activation. We found that both peptides greatly en-ELISA-type assay.
(C) Binding of FP10 to tPA was assessed as in (B). hance tPA-mediated plasmin formation (Figure 3C).
(D) tPA binding to FP13 and FP10 was assessed as in (B) and (C) Interestingly, the same peptides did not stimulate tPA-
with 200 nM tPA in the presence of the indicated concentrations of mediated plasminogen activation when they were used
ACA. immediately after solubilization (Figure 3C). Thioflavin
T binding to both peptides increased gradually over a
ably reflects cross- sheet conformation. The presence period of three weeks (our unpublished data). Thus, the
of cross- sheets can be demonstrated by X-ray diffrac- formation of cross- structure in the peptides is accom-
tion analysis [9]. When analyzed by X-ray diffraction, panied by an acquired ability to enhance tPA-mediated
plasmin generation.FP13 caused a distinct diffraction pattern, with reflection
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Figure 2. Structural Analysis of Fibrin-Derived Peptides
(A)The absorbance of circularly polarized light by solutions of FP13 and FP10 (0.1 mg/ml) was analyzed in a circular-dichroism spectropolarimeter
at the indicated wavelengths.
(B) Single drops of FP13 and FP10 (1 mg/ml in H2O) were air-dried and stained with Congo Red according to the manufacturer’s protocol.
Microscopic analysis with nonpolarized and polarized light shows that FP13, but not FP10 (not shown), binds Congo Red.
(C) Solutions of FP13 and FP10 were incubated with the indicated concentrations of thioflavin T, and fluorescence emission was measured
at 485 nm.
(D) X-ray diffraction analysis of FP13. The scattering as obtained on the 2D detector is color-coded by intensity on a linear scale. The scattering
intensity decreases as white-yellow-red-blue-black. The pattern shows diffraction maxima at 4.7, 11.7, and 23.4 A˚. In the lower panels,
tangential scans along the 2 scattering angles corresponding to all three d-spacings show that the 4.7 A˚ scattering (hydrogen bonds) is
perpendicular to that at 11.7 and 23.4 A˚ (1 and 2 intersheet distance).
(E) Solutions of FP13 and FP10 were spotted on a carbon-coated grid and analyzed by transmission EM. FP13, but not FP10, shows unbranched
amyloid-like fibers. The scale bar represents 200 nm.
Whereas the rate of A-stimulated plasmin formation and tPA binding. The lack of further rate-enhancement
during reactions with hIAPP may be explained by theis further enhanced during the reaction, that induced by
hIAPP is not. We have found that during A-stimulated fact that it has only one lysine residue that is located at
the extreme N terminus.plasmin formation limited proteolysis generates free in-
ternal lysines in A (O.K. et al., submitted). This may One of the amyloidogenic regions in hIAPP encom-
passes amino acid residues 20–29 [7, 11–14]. Diabeticenhance the reaction by allowing more plasminogen
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Figure 3. tPA Binding and Stimulation of Plasminogen Activation by A and hIAPP
(A) The binding of tPA to A was tested as in Figure 1B.
(B) The binding of tPA to hIAPP was tested as in Figure 1B.
(C) The stimulation of tPA-mediated plasminogen activation by A and hIAPP, either freshly resuspended or pre-aggregated for three weeks,
was tested as in Figure 1A.
(D) The activation of tPA by mouse and human “core” IAPP (cmIAPP, chIAPP) was tested as in Figure 1A.
(E) FP13, hIAPP, and A were incubated with plasminogen and with increasing concentrations of tPA. Plasmin formation was then assessed
as in Figure 1. The measured rates of plasmin generation in time with and without the peptides were then used for calculating the extent to
which the peptides stimulated plasmin generation. These values were subsequently plotted against the tPA concentrations. The peptides
loose their rate-enhancing effect at higher tPA concentrations.
(F) tPA, either at 0.2 nM or at 2 nM, was incubated with FP13, A, and hIAPP together with S-2765, a chromogenic peptide substrate for tPA.
tPA caused substrate conversion, but none of the cross- peptides stimulated tPA enzymatic activity.
mice, in contrast to diabetic humans, do not develop tion, albeit less efficiently than the full-length IAPP,
whereas cmIAPP was ineffective. When these resultspancreatic amyloid deposits because mouse IAPP
(mIAPP) has a different amino-acid sequence in this are taken together with the data on the fibrin peptides,
we have shown that four amyloid peptides (FP13, A,region and lacks the propensity to adopt cross- struc-
ture. We tested the presence of cross- structure in hIAPP, chIAPP) stimulate tPA-mediated plasmin forma-
tion, whereas two non-amyloid peptides (FP10, cmIAPP)these “core” regions in human and mouse IAPP (chIAPP,
cmIAPP) by Congo Red binding and compared their do not. Therefore, the results strongly suggest that tPA
binding and cofactor activity require the presence ofability to stimulate tPA-mediated plasminogen activa-
tion. As expected, Congo Red readily bound chIAPP, cross- structure in the peptides.
How do cross- peptides cause enhanced plasmino-but not cmIAPP; it showed green birefringence under
polarized light (our unpublished data). Figure 3D shows gen activation? Like fibrin, they could act as scaffolds
by promoting the interaction between enzyme (tPA) andthat chIAPP stimulated tPA-mediated plasmin forma-
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Figure 4. Enhanced Plasminogen Activation
by Cross--Structured Endostatin
(A) X-ray diffraction analysis of two distinct
forms of endostatin. The left panel shows
globular endostatin with no detectable
cross- sheets. The right panel shows insolu-
ble endostatin with abundant cross- sheets.
The scattering as obtained on the 2D detector
is color coded as in Figure 2D. The pattern
shows diffraction maxima at 4.7 and 10–11 A˚.
The fiber axis (hydrogen bond direction) with
a 4.7 A˚ repeat is oriented vertically. The
10–11 A˚ repeat is preferentially oriented per-
pendicularly to that, as indicated by the aster-
isk. Tangential scans along the 2 scattering
angles corresponding to both d spacings in
the lower panel show that the scattering at
4.7 A˚ is oriented vertically, with the maximum
intensity at 180 indicated by the arrow. The
reflection at 10–11 A˚ is oriented horizontally,
with the maximum at 90 indicated by the
asterisk.
(B) Stimulation of tPA-mediated plasminogen
activation by the two distinct forms of endo-
statin was assessed as in Figure 1A.
substrate (plasminogen). Alternatively, cross- peptides its (Figure 4A). Endostatin can also be isolated in a solu-
ble globular form that does not form cross- sheetsmay stimulate tPA enzymatic activity. With increasing
tPA and plasminogen concentrations, one would expect (Figure 4A). These two forms of endostatin allowed us
to compare the capacity of a single larger protein (20scaffold effects to diminish. In our assay, the tPA con-
centration is limiting. Therefore, we performed plasmin- kDa) in two distinct conformations (cross- versus non-
cross-) in the stimulation of tPA-mediated plasminogenogen activation assays with increasing concentrations
of tPA by using FP13, hIAPP, and A as cofactors. Figure activation. Figure 4B shows that endostatin with cross-
 structure potently stimulates tPA-mediated plasmino-3E shows that the stimulatory effect of the cross- pep-
tides on plasmin generation is lost with increasing con- gen activation like all the other cross- peptides but that
globular endostatin has no effect. Thus, the correlationcentrations of tPA. Next, we tested whether the cross-
peptides would stimulate tPA enzymatic activity. Figure between cross- structure and the ability to stimulate
tPA-mediated plasminogen activation holds for (short)3F shows that none of the tested peptides (FP13, IAPP,
and A) had a stimulatory effect on the conversion of peptides as well as for larger proteins.
the chromogenic peptide substrate S-2765 by tPA, nei-
ther at low (0.2 nM) nor at high (2 nM) concentrations Discussion
of the enzyme. Thus, cross- peptides act as scaffolds
for efficient plasminogen conversion by tPA without Our results provide evidence that tPA is a multiligand
receptor for proteins that display cross- structure.modulating tPA activity.
Finally, we tested whether cross- sheet formation in Upon binding to tPA, all cross- ligands tested stimulate
tPA-mediated plasmin formation. The tPA binding pep-larger proteins would also support tPA-mediated plas-
minogen activation. Firstly, it should be noted that tide sequences in fibrin have been identified [1], but no
structural data are available that show the basis of thiscross- sheet formation occurs during the polymeriza-
tion of fibrinogen into fibrin as measured by Raman interaction. Early data on the structural changes that
are associated with the conversion of fibrinogen intospectroscopy [15] and that this is accompanied by tPA-
activating potential. Secondly, we have recently found fibrin show that this is accompanied by a general in-
crease in  sheet content and by the formation of hydro-that endostatin, a 20 kDa fragment of the extracellular
matrix protein collagen XVIII, has the propensity to form gen bonds between lateral fibrin molecules [15]. This
type of interaction within the fibrin meshwork is similarcross- structure and to aggregate into amyloid depos-
Current Biology
1838
Supplementary Materialto that underlying the cross- sheet structure in amyloid
Supplementary Material, including the Experimental Procedures, ispeptide aggregates [6]. Furthermore, we show here that
available at http://images/cellpress.com/supmat/supmatin.htm.one of the isolated tPA binding regions in fibrin that
supports plasminogen activation has cross- structure. Acknowledgments
Thus, also in fibrin, tPA may bind to cross- sheet-
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